Trial Profile
A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behcet Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Behcet's syndrome; Genital ulcer; Oral ulcer; Panuveitis; Posterior uveitis; Retinal disorders; Vasculitis
- Focus Proof of concept; Therapeutic Use
- Acronyms STELABEC
- 02 Dec 2021 Primary endpoint has been met (Number of oral ulcers at week 24 compared to baseline)as per Results published in the Journal of the American Academy of Dermatology
- 02 Dec 2021 Results published in the Journal of the American Academy of Dermatology
- 12 Nov 2020 Status changed from active, no longer recruiting to completed.